English
Home > Products > CAS NO 1377049-84-7

China CAS NO 1377049-84-7 Factory

We know that we only thrive if we will guarantee our combined cost competiveness and high-quality advantageous at the same time for CAS NO 1377049-84-7,1377049-84-7,Velpatasvir API,Velpatasvir, We glance ahead to supplying you with our goods from the near long run, and you'll find our quotation is very acceptable plus the top quality of our goods is quite outstanding!
CAS NO 1377049-84-7, Our mission is to deliver consistently superior value to our customers and their clients. This commitment permeates everything we do, driving us to continuously develop and improve our solutions and the processes to fulfill your needs.

Related Products

Hot Products

  • D-(+)-Pantothenic acid calcium salt

    D-(+)-Pantothenic acid calcium salt

    Product Name:D-(+)-Pantothenic acid calcium salt
    Molecular Formula:C9H17NO5.1/2Ca
    Molecular Weight;476.53
    CAS Registry Number;137-08-6
  • Flurbiprofen

    Flurbiprofen

    Product Name:Flurbiprofen
    Molecular Formula:C15H13FO2
    Molecular Weight;244.27
    CAS Registry Number;5104-49-4
  • Raltegravir

    Raltegravir

    Product Name:Raltegravir
    Molecular Formula:C20H21FN6O5
    Molecular Weight;444.42
    CAS Registry Number;518048-05-0
  • 1,2,3-Trifluoro-4-nitrobenzene

    1,2,3-Trifluoro-4-nitrobenzene

    Product Name:1,2,3-Trifluoro-4-nitrobenzene
    Molecular Formula:C6H2F3NO2
    Molecular Weight:177.08
    CAS Registry Number:771-69-7
  • DOTA

    DOTA

    Product Name:DOTA
    Molecular Formula:C16H28N4O8
    Molecular Weight:404.42
    CAS Registry Number:60239-18-1
  • Atorvastatin tert-Butyl Ester

    Atorvastatin tert-Butyl Ester

    Product Name:Atorvastatin tert-Butyl Ester
    Molecular Formula:C37H43FN2O5
    Molecular Weight:614.75
    CAS Registry Number:134395-00-9
  • Related Blog
  • Reviews

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products...

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • What are pharmaceutical intermediates?

    Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept